Abstracts tagged "Cohort Study"

Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Reena Yaman¹, Lisa Balistreri², Maximiliano Diaz Menindez³, Sehreen Mumtaz¹, Megan Sullivan³, Alexander Hochwald¹ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Lee Health, Cape Coral, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1747 • ACR Convergence 2025
Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Mark Chaballa⁶, Vadim Khaychuk⁷, Misti Paudel⁸ and Jeffrey Sparks⁹, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Pennington, NJ, ⁸Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), contributes significantly to morbidity and mortality in RA patients. RA…
Abstract Number: 2060 • ACR Convergence 2025
Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
Irene Peralta-García¹, Naz Haque², Dag Leonard³, Anna Glasin⁴, Silva Puksic⁵, Balsam Hanna⁶, My Axelhed⁷, Theodoros Lappas⁵, Farbicio Espinosa Ortega¹, Karin Lodin¹, NIls Eckerdal², Helene Alexanderson⁸, Elizabeth Hsia⁹, Federico Zazzetti¹⁰, Ingrid Lundberg¹¹ and Marie Holmqvist¹, ¹Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden, ²Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology Department, Linköping Hospital, LInköping, Sweden, ⁵Rheumatology Department, Örebro University Hospital, Örebro, Sweden, ⁶Rheumatology Department, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁷Rheumatology Department, Västmanlands Hospital, Västerås, Sweden, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Johnson & Johnson, Spring House, PA, ¹⁰Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ¹¹Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Due to the rarity and heterogeneity of idiopathic inflammatory myopathies (IIM), we lack robust randomized trials to guide treatment decisions. Most of current practice…
Abstract Number: 2349 • ACR Convergence 2025
Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
Gözde Sevgi Kart bayram¹, Muhammed Çağrı Akdemir², Mustafa Ekici³, Gizem Ayan⁴, Büşra Fırlatan Yazgan¹, Erdinç Ünaldı³, Buğu Bulat¹, Ali Aytuğ Kuştaş³, Ali Akdoğan⁵, Omer Karadağ⁵, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Sedat Kiraz³, Umut Kalyoncu¹ and Levent Kılıç¹, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Ankara, Turkey, ⁴Ankara Research and Training Hospital, Ankara, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara
Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…
Abstract Number: 2607 • ACR Convergence 2025
ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Misti Paudel¹, Katherine Liao², Jon Giles³, Joan Bathon⁴, Hongshu Guan⁵, Brendan Everett⁶, Leah Santacroce⁷, Nancy Shadick⁸, Michael Weinblatt⁹, Pamela Rist⁶ and Daniel Solomon¹⁰, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ³Cedars Sinai Medical Center, Los Angeles, CA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham & Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Expanded Risk Model for Rheumatoid Arthritis (ERS-RA) incorporates traditional CV risk factors and RA-related measures of disease activity and has demonstrated better performance…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Lisa Lindsay¹, Shu Wang², Huong Trinh¹, Yunru Huang¹, William Pendergraft¹ and Brad Rovin³, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research LLC, Hoboken, NJ, ³The Ohio State University, Columbus, OH
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…

1
2
3
…
38
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].